期刊文献+

Arsenic trioxide up-regulates Fas expression in human osteosarcoma cells 被引量:10

Arsenic trioxide up-regulates Fas expression in human osteosarcoma cells
原文传递
导出
摘要 Background Osteosarcoma is a common primary malignant tumor of bone with a poor prognosis due to its propensity for metastasis. The prognosis of patients is highly dependent on the presence or absence of lung metastasis and on the effectiveness of treatment against it. It has been reported that low level expression of Fas protein in human osteosarcoma cell is closely associated with lung metastasis. A large number of studies have shown that arsenic trioxide (ATO) can inhibit proliferation and induce apoptosis of many cancer cell lines; however, its effects on human osteosarcoma cells (Saos-2 cell line) remains unknown. The aim of this study was to investigate the effects of ATO on Saos-2 cells and to characterize its mechanism of Fas-expressing. Methods A group of Saos-2 cells was treated with or without 0.5, 1, 2, 4 and 8 pmol/L ATO for three successive days, and the cytotoxicity of ATO was determined by an 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological changes in cells were studied by acridine orange/ethidium bromide (AO/EB) double staining. Flow cytometry (FCM) was used to assay cell DNA distribution. Another group of cells was pretreated with 10 nmol/L matrix metalloproteinase 7 (MMP-7) for 3 hours. They were then incubated with or without 2 pmol/L ATO for 24, 48 and 72 hours. Cytotoxicity, Fas protein and mRNA levels were systematically studied using MTT, Western blotting and real-time PCR, respectively. Cell proliferation, cell cycle progression and apoptosis were examined in this study. Results Proliferation of Saos-2 cells was inhibited by ATO in both a dose- and time-dependent manner. The IC50 values at 24, 48 and 72 hours were 9.30, 5.54 and 3.49 pmol/L, respectively. The survival rate of Saos-2 cells in the MMP-7 and ATO co-treated group was significantly higher than the ATO group, but it was lower than the control group. ATO induced G1 phase arrest of the cell cycle and very efficiently stimulated apoptosis in Saos-2 cells, as evidenced by flow cytometric detection of sub-G1 DNA content and AO/EB staining. Western blotting results indicated that Fas (FasL) protein expression in osteosarcoma cultures markedly increases in a time dependent manner after exposure to ATO. Compared with control, treatment with ATO 2 IJmol/L and 4 pmol/L for 48 hours, resulted in increase of Fas gene expression to 28.31% and 56.74%, respectively. Our results indicated that ATO induced-apoptosis of Saos-2 cells may be mediated through the Fas pathway. Conclusions ATO suppressed cell proliferation of Saos-2 cell in a dose- and time-dependent manner and increased Fas protein expression. However, Fas-mediated apoptosis was incompletely interrupted by MMP-7, which suggested that other molecular mechanisms may mediate this process. Background Osteosarcoma is a common primary malignant tumor of bone with a poor prognosis due to its propensity for metastasis. The prognosis of patients is highly dependent on the presence or absence of lung metastasis and on the effectiveness of treatment against it. It has been reported that low level expression of Fas protein in human osteosarcoma cell is closely associated with lung metastasis. A large number of studies have shown that arsenic trioxide (ATO) can inhibit proliferation and induce apoptosis of many cancer cell lines; however, its effects on human osteosarcoma cells (Saos-2 cell line) remains unknown. The aim of this study was to investigate the effects of ATO on Saos-2 cells and to characterize its mechanism of Fas-expressing. Methods A group of Saos-2 cells was treated with or without 0.5, 1, 2, 4 and 8 pmol/L ATO for three successive days, and the cytotoxicity of ATO was determined by an 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Morphological changes in cells were studied by acridine orange/ethidium bromide (AO/EB) double staining. Flow cytometry (FCM) was used to assay cell DNA distribution. Another group of cells was pretreated with 10 nmol/L matrix metalloproteinase 7 (MMP-7) for 3 hours. They were then incubated with or without 2 pmol/L ATO for 24, 48 and 72 hours. Cytotoxicity, Fas protein and mRNA levels were systematically studied using MTT, Western blotting and real-time PCR, respectively. Cell proliferation, cell cycle progression and apoptosis were examined in this study. Results Proliferation of Saos-2 cells was inhibited by ATO in both a dose- and time-dependent manner. The IC50 values at 24, 48 and 72 hours were 9.30, 5.54 and 3.49 pmol/L, respectively. The survival rate of Saos-2 cells in the MMP-7 and ATO co-treated group was significantly higher than the ATO group, but it was lower than the control group. ATO induced G1 phase arrest of the cell cycle and very efficiently stimulated apoptosis in Saos-2 cells, as evidenced by flow cytometric detection of sub-G1 DNA content and AO/EB staining. Western blotting results indicated that Fas (FasL) protein expression in osteosarcoma cultures markedly increases in a time dependent manner after exposure to ATO. Compared with control, treatment with ATO 2 IJmol/L and 4 pmol/L for 48 hours, resulted in increase of Fas gene expression to 28.31% and 56.74%, respectively. Our results indicated that ATO induced-apoptosis of Saos-2 cells may be mediated through the Fas pathway. Conclusions ATO suppressed cell proliferation of Saos-2 cell in a dose- and time-dependent manner and increased Fas protein expression. However, Fas-mediated apoptosis was incompletely interrupted by MMP-7, which suggested that other molecular mechanisms may mediate this process.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第13期1768-1773,共6页 中华医学杂志(英文版)
关键词 arsenic trioxide SAOS-2 FAS Fas ligand matrix metalloproteinase 7 arsenic trioxide Saos-2 Fas Fas ligand matrix metalloproteinase 7
  • 相关文献

参考文献2

二级参考文献23

  • 1郭卫,杨荣利,汤小东,唐顺,李大森,杨毅.成骨肉瘤新辅助化学药物治疗的疗效分析[J].中华医学杂志,2004,84(14):1186-1190. 被引量:24
  • 2方成,陈振光,喻爱喜,祝少博.三氧化二砷诱导骨肉瘤细胞凋亡的实验研究[J].中华骨科杂志,2003,23(6):345-348. 被引量:17
  • 3汤小东,郭卫,李大森.三氧化二砷诱导尤文肉瘤细胞凋亡及对EWS-FLi1融合蛋白的影响[J].中国肿瘤临床,2005,32(22):1280-1283. 被引量:1
  • 4Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician, 2002, 65 : 1123-1132.
  • 5Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br, 2002, 84: 88-92.
  • 6Meyers PA, Gorlick R, Heller G, et al. Intensification of Preoperative Chemotherapy for Osteogenic Sarcoma: Results of the Memorial Sloan-Kettering (T12) Protocol. J Clin Oncol, 1998, 16 :2452-2458.
  • 7Kushner BH, Meyem PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol, 2001, 19: 870-880.
  • 8Guo W, Healey JH, Meyers PA, et al. Mechanisms of Methotrexate Resistance in Osteosarcoma. Clin Cancer Res, 1999, 5:621-627.
  • 9Guo W, Zeng C, Dong F, et al. Paclitaxel-induced apoptosis in osteosarcoma cell line U-2 OS. Chin Med J ( Engl ), 2002, 115 :1796-1801.
  • 10Mervis J. Ancient remedy performs new tricks. Science, 1996, 273 :578.

共引文献51

同被引文献53

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部